Zentalis Pharmaceuticals Net Worth
Zentalis Pharmaceuticals Net Worth Breakdown | ZNTL |
Zentalis Pharmaceuticals Net Worth Analysis
Zentalis Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Zentalis Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Zentalis Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Zentalis Pharmaceuticals' net worth analysis. One common approach is to calculate Zentalis Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Zentalis Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Zentalis Pharmaceuticals' net worth. This approach calculates the present value of Zentalis Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Zentalis Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Zentalis Pharmaceuticals' net worth. This involves comparing Zentalis Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Zentalis Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Zentalis Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Zentalis Pharmaceuticals' net worth research are outlined below:
| Zentalis Pharmaceuticals generated a negative expected return over the last 90 days | |
| Zentalis Pharmaceuticals has high historical volatility and very poor performance | |
| Zentalis Pharmaceuticals may become a speculative penny stock | |
| Zentalis Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (292.19 M) with profit before overhead, payroll, taxes, and interest of 40.56 M. | |
| Zentalis Pharmaceuticals Llc currently holds about 455.22 M in cash with (207.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.99, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Zentalis Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 94.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Insider Trading |
Zentalis Pharmaceuticals Quarterly Good Will |
|
Zentalis Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Zentalis Pharmaceuticals Llc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Zentalis Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Zentalis Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Zentalis Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Zentalis Pharmaceuticals Llc backward and forwards among themselves. Zentalis Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Zentalis Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2024-12-31 | 1.3 M | D. E. Shaw & Co Lp | 2024-12-31 | 1.2 M | Verition Fund Managegment, Llc | 2024-12-31 | 1.2 M | Mpm Oncology Impact Management Lp | 2024-12-31 | 1.1 M | Integral Health Asset Management, Llc | 2024-12-31 | 1.1 M | T. Rowe Price Associates, Inc. | 2024-12-31 | 979.9 K | Tybourne Capital Management (hk) Ltd | 2024-12-31 | 961.5 K | Millennium Management Llc | 2024-12-31 | 957.6 K | Pfizer Inc | 2024-12-31 | 953.8 K | Matrix Capital Management Company, Llc | 2024-12-31 | 14 M | Eventide Asset Management, Llc | 2024-12-31 | 4.5 M |
Follow Zentalis Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 141.11 M.Market Cap |
|
Project Zentalis Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.48) | (0.50) | |
| Return On Capital Employed | (0.46) | (0.49) | |
| Return On Assets | (0.48) | (0.50) | |
| Return On Equity | (0.60) | (0.63) |
When accessing Zentalis Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Zentalis Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Zentalis Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Zentalis Pharmaceuticals' management efficiency
Zentalis Pharmaceuticals has return on total asset (ROA) of (0.2524) % which means that it has lost $0.2524 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4289) %, meaning that it created substantial loss on money invested by shareholders. Zentalis Pharmaceuticals' management efficiency ratios could be used to measure how well Zentalis Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.5. The value of Return On Capital Employed is expected to slide to -0.49. At this time, Zentalis Pharmaceuticals' Net Tangible Assets are quite stable compared to the past year. Non Currrent Assets Other is expected to rise to about 11.5 M this year, although the value of Non Current Assets Total will most likely fall to about 54.9 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 6.02 | 4.76 | |
| Tangible Book Value Per Share | 5.97 | 4.55 | |
| Enterprise Value Over EBITDA | (3.29) | (3.45) | |
| Price Book Value Ratio | 2.61 | 2.48 | |
| Enterprise Value Multiple | (3.29) | (3.45) | |
| Price Fair Value | 2.61 | 2.48 | |
| Enterprise Value | 1.9 B | 1.1 B |
Understanding the operational decisions made by Zentalis Pharmaceuticals management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Zentalis Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Zentalis Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Zentalis Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Zentalis Pharmaceuticals time-series forecasting models is one of many Zentalis Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Zentalis Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Zentalis Pharmaceuticals Earnings per Share Projection vs Actual
Zentalis Pharmaceuticals Corporate Management
| Vincent Vultaggio | VP Officer | Profile | |
| Kevin Bunker | CoFounder Officer | Profile | |
| Carrie MD | Chief Officer | Profile | |
| Adrian MD | Executive Development | Profile | |
| Mark Lackner | Chief Strategy | Profile | |
| Ingmar MD | Chief Officer | Profile | |
| Kimberly Freeman | Chief Officer | Profile |
Already Invested in Zentalis Pharmaceuticals Llc?
The danger of trading Zentalis Pharmaceuticals Llc is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Zentalis Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Zentalis Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Zentalis Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Zentalis Pharmaceuticals is a strong investment it is important to analyze Zentalis Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zentalis Pharmaceuticals' future performance. For an informed investment choice regarding Zentalis Stock, refer to the following important reports: Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zentalis Pharmaceuticals Llc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis Pharmaceuticals. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Zentalis Pharmaceuticals is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zentalis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zentalis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zentalis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.